DKK3 and glioblastoma: Particularly, significant decreases in DKK3 were observed in human glioblastoma cell lines, as well as in U-87 MG xenograft tumors and in GB human patients’ tissues, highlighting that a combined modulation of the WNT/DKK3 pathways, simultaneously targeting apoptosis and survival signaling defects, might shift the balance from tumor growth stasis to cytotoxic therapeutic responses, resulting in greater therapeutic benefits.